UBS has given Sartorius a 'Neutral' rating and a target price of 264 euros after the company released its third-quarter figures.
The laboratory services provider reported sales that were lower than expected, but operating profit was in line with expectations, according to analyst Matthew Weston.
The report mentions a potential positive trend, noting a recovery in orders within Sartorius' BPS division, which could have a positive impact on the market.